United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Click ...

United Therapeutics navigates competition with solid Q1 results, revenue growth projections, and a solid balance sheet. Learn ...

Fintel reports that on June 2, 2025, Cantor Fitzgerald initiated coverage of United Therapeutics (NasdaqGS:UTHR) with a ...

United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further ...

It has been about a month since the last earnings report for United Therapeutics (UTHR). Shares have added about 9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

In the last three months, 7 analysts have published ratings on United Therapeutics UTHR, offering a diverse range of perspectives from bullish to bearish. The following table summarizes their ...

United Therapeutics UTHR shares soared 3.5% in the last trading session to close at $286.14. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

On Wednesday, Leerink Partners analysts reaffirmed their Outperform rating for United Therapeutics Corp . (NASDAQ:UTHR) and maintained a price target of $418.00. This decision comes as the company ...